Cipher Pharmaceuticals is improving drugs for better results.

We are a specialty pharmaceutical company that develops improved formulations of existing drugs. We search for products in defined markets to in-license into our pipeline. These products are based on currently marketed molecules paired with a novel drug delivery technology for enhanced performance. Our core competency is identifying these product opportunities and managing their clinical and regulatory development. Finally, we harvest the rewards by out-licensing to international partners and generating royalty streams.

Because Cipher’s products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs.

We have made strong progress since the Company was founded in 2000. We have in-licensed three products and successfully achieved U.S. FDA and Health Canada approvals for the first product, a tentative FDA approval for the second, while the third has entered its final Phase III safety trial.